Skip to Content
Merck
CN

B7688

PiB

≥98% (HPLC)

Sign In to View Organizational & Contract Pricing.

Select a Size


About This Item

Empirical Formula (Hill Notation):
C22H18N2O8
CAS Number:
Molecular Weight:
438.39
NACRES:
NA.77
PubChem Substance ID:
UNSPSC Code:
12352200
MDL number:
Assay:
≥98% (HPLC)
Form:
powder
Quality level:
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

InChI key

WNKQGFNIIHNGQM-UHFFFAOYSA-N

SMILES string

O=C(C1=C2C(C3=CC=C24)=C(C(N(CC(OCC)=O)C3=O)=O)C=C1)N(CC(OCC)=O)C4=O

InChI

1S/C22H18N2O8/c1-3-31-15(25)9-23-19(27)11-5-7-13-18-14(8-6-12(17(11)18)20(23)28)22(30)24(21(13)29)10-16(26)32-4-2/h5-8H,3-4,9-10H2,1-2H3

assay

≥98% (HPLC)

form

powder

color

white to light brown

solubility

DMSO: 1-2 mg/mL (warmed)

storage temp.

2-8°C

Quality Level

Biochem/physiol Actions

PiB is a Pin-1 inhibitor.
PiB is an inhibitor of the peptidylprolyl isomerase Pin-1. Inhibition of Pin-1 leads to destabilization of the transcription factor Nanog, which is required for maintenance of embryonic stem cell cultures.

Storage Class

11 - Combustible Solids

wgk

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Stephan Müller et al.
Scientific reports, 7(1), 1225-1225 (2017-04-30)
The relationship between body-mass index (BMI) and Alzheimer´s disease (AD) has been extensively investigated. However, BMI alterations in preclinical individuals with autosomal dominant AD (ADAD) have not yet been investigated. We analyzed cross-sectional data from 230 asymptomatic members of families
Lisa Vermunt et al.
Neurology, 92(23), e2699-e2705 (2019-05-10)
To identify potential predictors for outcome in individuals with mild cognitive impairment (MCI) who have reverted to normal cognition (NC). We selected individuals with MCI, who reverted at follow-up to NC, with follow-up after reversion from Alzheimer's Disease Neuroimaging Initiative.
Takamasa Yokoi et al.
Frontiers in aging neuroscience, 10, 304-304 (2018-10-23)
Background: Imaging studies in Alzheimer's disease (AD) have yet to answer the underlying questions concerning the relationship among tau retention, neuroinflammation, network disruption and cognitive decline. We compared the spatial retention patterns of 18F-THK5351 and resting state network (RSN) disruption
Bernard J Hanseeuw et al.
Alzheimer's & dementia : the journal of the Alzheimer's Association, 14(10), 1281-1292 (2018-05-25)
Amyloid positron emission tomography (PET) data are commonly expressed as binary measures of cortical deposition. However, not all individuals with high cortical amyloid will experience rapid cognitive decline. Motivated by postmortem data, we evaluated a three-stage PET classification: low cortical;
Jun Ho Lee et al.
Frontiers in aging neuroscience, 10, 309-309 (2018-10-20)
Background: Given the barriers prohibiting the broader utilization of amyloid imaging and high screening failure rate in clinical trials, an easily available and valid screening method for identifying cognitively impaired patients with cerebral amyloid deposition is needed. Therefore, we developed

Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.

Contact Technical Service